MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
101.56
-0.34
-0.33%
After Hours: 101.77 +0.21 +0.21% 17:51 12/31 EST
OPEN
101.81
PREV CLOSE
101.90
HIGH
101.95
LOW
101.55
VOLUME
1.47M
TURNOVER
--
52 WEEK HIGH
102.66
52 WEEK LOW
38.81
MARKET CAP
19.27B
P/E (TTM)
-19.1010
1D
5D
1M
3M
1Y
5Y
1D
3 Unpopular Stocks We Steer Clear Of
Barchart · 12/31/2025 10:00
EXACT SCIENCES SHAREHOLDERS UNHAPPY WITH $105 PER SHARE SALE TO ABBOTT SHOULD CONTACT JULIE & HOLLEMAN LLP REGARDING POTENTIAL CLAIMS
Reuters · 12/30/2025 14:31
How Tempus AI Is Building Scale While Near-Term Risks Persist
NASDAQ · 12/30/2025 12:32
Should You Continue to Hold EXAS Stock in Your Portfolio Now?
NASDAQ · 12/30/2025 12:32
Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger
TipRanks · 12/29/2025 13:59
Exact Sciences Corporation Announces Date for Upcoming Special Stockholders Meeting
Reuters · 12/29/2025 13:46
Exact Sciences Approves Accelerated Bonus and Equity Vesting for Executives Ahead of Abbott Merger
Reuters · 12/29/2025 13:34
Weekly Report: what happened at EXAS last week (1222-1226)?
Weekly Report · 12/29/2025 09:44
More
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Webull offers Exact Sciences Corp stock information, including NASDAQ: EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.